Trial · NCT05359692
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT05359692, Phase 2, Withdrawn, Incyte Biosciences International Sàrl
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Trials, record NCT05359692. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05359692
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- NCT number
- NCT05359692
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Incyte Biosciences International Sàrl
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- INCAGN01876, retifanlimab
- First posted
- 2022-05-04
- Last updated
- 2023-09-15
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Participants With Treatment-Emergent Adverse Events (TEAEs) | Screening through 90 days after end of treatment, up to 24 months | A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after the first dose of study treatment. |
| Primary | Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | Assessed every 8 weeks for 12 months, thereafter every 12 weeks up to the end of treatment, up to 24 months. | Defined as the percentage of participants having complete response (CR) or partial response (PR). |
| Secondary | Duration of response (DOR) based on RECIST v1.1 and mRECIST | Assessed every 8 weeks for 12 months, then every 12 weeks, up to 24 months. | Defined as the time from the earliest date of disease response (CR or PR) until earliest date of disease progression or death due to any cause. |
| Secondary | Disease control rate (DCR) based on RECIST v1.1 and mRECIST | Assessed every 8 weeks for 12 months, then every 12 weeks, up to 24 months. | Defined as the percentage of participants having CR, PR, or stable disease (SD). |
| Secondary | Progression-free survival (PFS) based on RECIST v1.1 and mRECIST | Assessed every 8 weeks for 12 months, then every 12 weeks, up to 24 months. | Defined as the time from the start of combination therapy until the earliest date of disease progression or death due to any cause. |
| Secondary | Part 2: Participants With Treatment-Emergent Adverse Events (TEAEs) | Screening through 90 days after end of treatment, up to 24 months | A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after the first dose of study treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05359692
GET https://conductscience.org/api/trials/v1/NCT05359692/registered